Healthcare News

Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Analysis by Future Trends, Demand, Application & Tech Updates

Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market

Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market estimated to be valued US$ 184 Mn in 2017 and poised to grow at CAGR of 8.1% over 2017-2023. Market for Bile Duct Cancer (Cholangiocarcinoma) Treatment projected to reach US$ 293 Mn by 2023 owing to growing prevalence of bile duct cancer and incidence of liver fluke infections in developing countries

Get PDF Sample Brochure @ https://decisionmarketreports.com/request-sample?productID=974350

Growing prevalence of liver and bile duct cancer in developed and developing markets driving market revenue growth

The market for bile duct cancer treatment is growing at healthy CAGR across the globe owing to rising incidence and prevalence of bile duct cancer across the globe. Moreover, the significant market growth has been observed in developing regions of Asia-pacific and Middle Eastern regions owing to common parasitic infection of the bile duct in these regions. For instance, according to The Cholangiocarcinoma Foundation, About 6,000 people in the United States develop bile duct cancer each year and Bile duct cancer is much more common in Asia and the Middle East, mostly because of a common parasitic infection of the bile duct.

Rising industrialization and orphan drug designation for bile duct cancer therapies likely impact market growth positively  

The industrialization in developing counters such as India, China, and other ASEAN countries led to increased exposure to harmful chemicals that are affecting the workers and leading to growth in the incidence of bile duct cancer among the industrial workforce, which is expected to drive market growth positively over the forecast period. Moreover, growing number of drugs has been awarded Orphan drug designation, which also expected to increase the market access and product demand across the globe and leading to lucrative market opportunities for the players in the market. For instance, in 2017 RedHill Bio received orphan drug designation for YELIVA (ABC294640) in the treatment of cholangiocarcinoma.

Know More @ https://decisionmarketreports.com/market-reports/974350/bile-duct-cancer-cholangiocarcinoma-treatment-market

Asia-Pacific emerged as prominent region for Bile Duct Cancer (Cholangiocarcinoma) Treatment Market across the globe

The Asia-Pacific market is expected to hold the larger revenue share in global bile Duct Cancer (Cholangiocarcinoma) Treatment Market and projected to remain dominant over the forecast period owing to growing prevalence and incidence of bile duct cancer in the region. North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market projected to grow at highest CAGR over the forecast period in comparison with other regions owing to orphan designation status for drug molecules in the recent times for treating cholangiocarcinoma

Competition Assessment

Key players profiled in the global Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market include:

  • Accord Healthcare Inc. (UK)
  • Bristol-Myers Squibb Company (U.S)
  • Celgene Corporation (U.S)
  • Delcath Systems Inc. (U.S)
  • Eli Lilly and Company. (U.S)
  • F. Hoffman-La Roche AG (Switzerland)
  • Fresenius Kabi AG (Germany)
  • Johnson & Johnson Services Inc. (U.S)
  • Kyowa Hakko Kirin Co Ltd. (Japan)
  • Mylan N.V. (U.S)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (U.S)
  • Sanofi (France)
  • Teva Pharmaceuticals Industries Ltd. (Israel)

Players in bile Duct Cancer (Cholangiocarcinoma) Treatment Market market are focusing on introducing newer and innovative therapies to garner larger market revenue share in global cholangiocarcinoma (bile duct cancer) treatment market.

Key Findings of the Report:

 

  • Global bile Duct Cancer (Cholangiocarcinoma) Treatment Market expanding at 8.1 % CAGR over 2017 to 2023 to reach market value of US$ 293 Mn by 2023
  • Based on treatment type, Gemcitabine Combination Therapy segment accounted for larger revenue share in 2016 owing to larger adoption in bile duct cancer treatment
  • Extrahepatic bile duct cancer disease indication segment expected to hold larger revenue share in global market over the forecast period
  • Hospital Pharmacies are prominent source for cholangiocarcinoma (bile duct cancer) therapies and accounted for larger market revenue share in 2016 expected to remain attractive over the forecast period

 

Key Features of the Report:

 

  • The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

 

Detailed Segmentation

 

By Therapy Type

  • Drug Therapy
    • Gemcitabine Combination Therapy
    • 5-fluorouracil Combination Therapy
    • Capecitabine Combination Therapy
    • Gemcitabine Alone
  • Radiation Therapy
    • Brachytherapy
    • External Beam Radiation Therapy (EBRT)
  • Surgery

 

By Disease Indication

  • Intrahepatic Bile Duct Cancer
  • Extrahepatic Bile Duct Cancer
    • Perihilar Bile Duct Cancer
    • Distal Extrahepatic Bile Duct Cancer

 

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

 

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Russia
    • Poland
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia & New Zealand
    • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Venezuela
    • Rest of Latin America
  • The Middle East and Africa (MEA)
    • Gulf Cooperation Council (GCC) Countries
    • Israel
    • South Africa
    • Rest of MEA

About Us
Decision Market Reports is a one-stop solution, covers market research studies of all the industries, companies and regions. DMR aims at providing quality research, and insights about every market to helps our clients in taking right decisions. Our repository consists of most trending industry reports, niche areas, and leading company profiles. A comprehensive collection of reports is updated daily to offer hassle-free access to our latest updated report databases.

Contact Us
Gasper James
304, S Jones Blvd,
Las Vegas,
NV 89107, USA
US Toll Free +18666051052
Email: [email protected]
Web: http://decisionmarketreports.com/

About the author

Decision Market Reports

Decision Market Reports is a one-stop solution, covers market research studies of all the industries, companies and regions. DMR aims at providing quality research, and insights about every market to helps our clients in taking right decisions. Our repository consists of most trending industry reports, niche areas, and leading company profiles. A comprehensive collection of reports is updated daily to offer hassle-free access to our latest updated report databases.